@article{025af0cf8ed94d6db3623deb18546f29,
title = "Targeting signaling pathways in inflammatory breast cancer",
abstract = "Inflammatory breast cancer (IBC), although rare, is the most aggressive type of breast cancer. Only 2–4% of breast cancer cases are classified as IBC, but—owing to its high rate of metastasis and poor prognosis—8% to 10% of breast cancer-related mortality occur in patients with IBC. Currently, IBC-specific targeted therapies are not available, and there is a critical need for novel therapies derived via understanding novel targets. In this review, we summarize the biological functions of critical signaling pathways in the progression of IBC and the preclinical and clinical studies of targeting these pathways in IBC. We also discuss studies of crosstalk between several signaling pathways and the IBC tumor microenvironment.",
keywords = "Clinical trials, Inflammatory breast cancer, Signaling pathways, Targeted therapy, Tumor microenvironment",
author = "Xiaoping Wang and Takashi Semba and Phi, {Lan Thi Hanh} and Sudpreeda Chainitikun and Toshiaki Iwase and Bora Lim and Ueno, {Naoto T.}",
note = "Funding Information: Funding: This work was funded by the Emerson Collective Cancer Research Fund 689199 (X.W.), Breast Cancer Research Foundation (BCRF-17-161), Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, State of Texas Rare and Aggressive Breast Cancer Research Program, National Institutes of Health 1R01CA205043-01A1 (N.T.U.), and the MD Anderson Cancer Center Support Grant from the US National Cancer Institute (CA016672). Funding Information: This work was funded by the Emerson Collective Cancer Research Fund 689199 (X.W.), Breast Cancer Research Foundation (BCRF-17-161), Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, State of Texas Rare and Aggressive Breast Cancer Research Program, National Institutes of Health 1R01CA205043-01A1 (N.T.U.), and the MD Anderson Cancer Center Support Grant from the US National Cancer Institute (CA016672). Acknowledgments: The authors thank Bryan Tutt (Editing Services, Research Medical Library, The University of Texas MD Anderson Cancer Center) for his expert editorial assistance. Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2020",
month = sep,
doi = "10.3390/cancers12092479",
language = "English (US)",
volume = "12",
pages = "1--19",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",
}